Global Blood Therapeutics Inc. (NASDAQ: GBT) is 131.94% higher on its value in year-to-date trading and has touched a low of $21.65 and a high of $73.02 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The GBT stock was last observed hovering at around $68.03 in the last trading session, with the day’s loss setting it -0.14%.
Currently trading at $67.89, the stock is 0.22% and 23.49% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 3.63 million and changing -0.21% at the moment leaves the stock 88.46% off its SMA200. GBT registered 150.52% gain for a year compared to 6-month gain of 111.17%.
The stock witnessed a 1.30% loss in the last 1 month and extending the period to 3 months gives it a 137.54%, and is 0.21% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 0.45% over the week and 0.48% over the month.
Global Blood Therapeutics Inc. (GBT) has around 457 employees, a market worth around $4.59B and $234.90M in sales. Distance from 52-week low is 213.58% and -7.03% from its 52-week high. The company has generated returns on investments over the last 12 months (-37.10%).
Global Blood Therapeutics Inc. (GBT) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Global Blood Therapeutics Inc. (GBT) is a “Hold”. 16 analysts offering their recommendations for the stock have an average rating of 2.70, where 14 rate it as a Hold and 0 think it is a “Overweight”. 2 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Global Blood Therapeutics Inc. is expected to release its quarterly report on 11/03/2022.The EPS is expected to shrink by -19.30% this year.
Global Blood Therapeutics Inc. (GBT) Top Institutional Holders
The shares outstanding are 65.59M, and float is at 62.83M with Short Float at 10.97%.
Global Blood Therapeutics Inc. (GBT) Insider Activity
A total of 29 insider transactions have happened at Global Blood Therapeutics Inc. (GBT) in the last six months, with sales accounting for 12 and purchases happening 17 times. The most recent transaction is an insider sale by Farrow Jeffrey S,the company’sChief Financial Officer. SEC filings show that Farrow Jeffrey S sold 31,441 shares of the company’s common stock on Sep 01 at a price of $68.00 per share for a total of $2.14 million. Following the sale, the insider now owns 3086.0 shares.
Global Blood Therapeutics Inc. disclosed in a document filed with the SEC on Aug 18 that Habibizad Nazilasold a total of 4,678 shares of the company’s common stock. The trade occurred on Aug 18 and was made at $67.19 per share for $0.31 million. Following the transaction, the insider now directly holds 8918.0 shares of the GBT stock.
Still, SEC filings show that on Jun 21, Svoronos Dawn (Director) disposed off 1,908 shares at an average price of $27.24 for $51983.0. The insider now directly holds 5,376 shares of Global Blood Therapeutics Inc. (GBT).
Global Blood Therapeutics Inc. (GBT): Who are the competitors?
The company’s main competitors (and peers) include Omeros Corporation (OMER) that is -75.64% lower over the past 12 months.